 |
138 Diseases |  |
94 Trials |
|
94 Trials |  |
2090 News |  |
| «12...7891011121314151617...3233» |
- | Firmagon (degarelix) / Astellas, Ferring
Observational data, Journal: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan. (Pubmed Central) - Jun 8, 2022
In patients with PCa and pre-existing CVD, GnRH antagonist use was associated with lower risks for composite CV events and MACE compared with GnRHa.
- |||||| leuprolide acetate for depot suspension / Generic mfg., Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Clinical: Efficacy and safety of relugolix in men with adv #ProstateCancer based on baseline BMI: subgroup analysis from the randomized, phase 3 #HERO study vs leuprolide. Presentation by Fred Saad @chumontreal. #ASCO22 written coverage by @zklaassen_md > https://t.co/1JnFmi8dCQ @PCFnews (Twitter) - Jun 7, 2022
- || leuprolide acetate for depot suspension / Generic mfg.
I was on Lupron and still progressing until Oopherectomy so very interesting to me. (Twitter) - Jun 6, 2022
- ||||| leuprolide acetate for depot suspension / Generic mfg., Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Clinical: Subgroup analysis from HERO: Efficacy and safety of relugolix based on baseline BMI ✅Castration rates: ⬆️ for the relugolix v leuprolide across all BMI subgroups ✅PSA response proportions: lower in obese men ✅No differences in AEs @urotoday #ASCO22 (Twitter) - Jun 6, 2022
- | leuprolide acetate for depot suspension / Generic mfg.
Preclinical, Journal: Estropause, Sex Hormones and Metal Homeostasis in the Mouse Brain. (Pubmed Central) - Jun 4, 2022
To assess whether age-related changes in hypothalamic-pituitary-gonadal (HPG) hormones might be involved in modulating brain metal ion homeostasis, we treated 7.5-month intact, sham-ovariecomized and ovariectomized C57B6SJL mice with vehicle or leuprolide acetate (for 9-months) to differentiate between whether sex steroids or gonadotropins might modulate brain metal ion concentrations...This study demonstrates that sex hormones do not markedly alter brain metal ion homeostasis, unlike previously reported studies of circulating metal ion homeostasis. The role of gonadotropins in regulating metal ion homeostasis does however warrant further study.
- | leuprolide acetate for depot suspension / Generic mfg.
Lucrin Depot neden bulamıyoruz eczanelerde sürekli zam gelecek depolar elinde tutuyor bilgisi alıyoruz . (Twitter) - Jun 1, 2022
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Hydroxyl Group-Targeted Conjugate and Its Self-Assembled Nanoparticle of Peptide Drug: Effect of Degree of Saturation of Fatty Acids and Modification of Physicochemical Properties. (Pubmed Central) - May 29, 2022
To conjugate different degree of saturation of C18 fatty acids (stearic acid, oleic acid, and linoleic acid) with the hydroxyl groups of leuprolide acetate (LEU acetate) and to investigate the controlled release and enhanced permeability through self-assembled nanoparticles (L18FNs)...While the permeability of LSNs was not significantly enhanced due to higher particle size after nanonization, LONs and LLNs increased 1.56 and 1.85 times in permeation, respectively, compared to LEU. Utilization of different degree of saturation of fatty acids to conjugate a peptide drug could provide pharmaceutical versatility via self-assembly and modification of physicochemical properties.
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Journal: Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists. (Pubmed Central) - May 29, 2022
Overall, one in four urologists were classified as high mono-prescribers. Mono-prescribers had more years in practice and smaller volume practices, potentially suggesting habitual prescription behavior and/or the effect of external pressures.
- leuprolide acetate for depot suspension / Generic mfg.
Clinical and surgical predictors of urinary tract endometriosis after primary surgical treatment: A single high-volume centre experience (Yellow Area, Room Forum) - May 23, 2022 - Abstract #EAU2022EAU_2602;
Age at first surgery <30 years and presence of concomitant autoimmune disease at diagnosis were confirmed as independent predictors of DIE recurrence. Adjuvant hormonal treatment in such patients may have a role in preventing disease recurrence.
- ||| leuprolide acetate for depot suspension / Generic mfg.
Clinical: Does he have prostatitis on biopsy? Treat BPH and see if prostatitis resolves. I had a patient once had PSA 100,000 with adenopathy all over his body. Was about to have surgery for a neck mass. Prostate biopsy was negative. Disease free 14 years later after Lupron. (Twitter) - May 22, 2022
- ||| leuprolide acetate for depot suspension / Generic mfg.
Clinical: I agree with this, and I have not seen obvious patterns to explain. Unrelated to this specific question, I have observed that patients started on 6-month leuprolide depot frequently experience severe hot flashes and I am favoring shorter forms (including oral) more and more. (Twitter) - May 22, 2022
- || leuprolide acetate for depot suspension / Generic mfg., Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Dr. Chu discusses the results of the HERO trial comparing relugolix and leuprolide @NEJM (Twitter) - May 20, 2022
- ||| leuprolide acetate for depot suspension / Generic mfg., Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
@amirsali101 Can you share with us proof that competition stabilizes prices? It didnt for PD-L1 in lung cancers. Relugolix didnt bring down price for lupron, instead it got more expensive. Id like to see some data to back the claim you just made. (Twitter) - May 18, 2022
- |||| Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Trial completion date, Trial primary completion date: PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov) - May 11, 2022
P3, N=504, Recruiting, Sponsor: Alliance Foundation Trials, LLC.
Adjuvant hormonal treatment in such patients may have a role in preventing disease recurrence. Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- | Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Journal: THE CARDIOVASCULAR EFFECTS OF GNRH ANTAGONISTS IN MEN WITH PROSTATE CANCER. (Pubmed Central) - May 11, 2022
Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 There is consistent but methodologically limited data to suggest that GnRH antagonists-a relatively new class of androgen deprivation therapy for prostate cancer-cause significantly less cardiovascular adverse effects than the more frequently used GnRH agonists.
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - May 9, 2022
P3, N=3246, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
There is consistent but methodologically limited data to suggest that GnRH antagonists-a relatively new class of androgen deprivation therapy for prostate cancer-cause significantly less cardiovascular adverse effects than the more frequently used GnRH agonists. Trial completion date: Jun 2022 --> Sep 2022
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Efficacy of Laparoscopic Surgery Combined With Leuprorelin in the Treatment of Endometriosis Associated With Infertility and Analysis of Influencing Factors for Recurrence. (Pubmed Central) - May 7, 2022
Preoperative dysmenorrhea is an independent risk factor for postoperative recurrence, which should be quantified and included in the recurrence risk prediction model. Postoperative pregnancy can reduce the recurrence rate after operation, and patients with fertility requirements should be encouraged to make activ preparations for postoperative pregnancy.
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial withdrawal: BASH-PC: Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer (clinicaltrials.gov) - May 2, 2022
P2, N=0, Withdrawn, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Postoperative pregnancy can reduce the recurrence rate after operation, and patients with fertility requirements should be encouraged to make activ preparations for postoperative pregnancy. N=20 --> 0 | Suspended --> Withdrawn
- ||| leuprolide acetate for depot suspension / Generic mfg.
Clinical: Thank you, Dr. Shatsky! If this patient had node+ve disease, in that scenario (BMI: 60), would you consider Tamox/Abema or would you lean towards Abema/AI/Lupron? Dr. @stolaney1 had recently discussed about increased ⬆️ VTE with Abema/Tamox. 🙏🏽🙏🏽 (Twitter) - Apr 29, 2022
- || leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Important to remember that 24 months high-dose bicalutamide ≠ 24 months leuprolide; perhaps more like 12-18 months. (Twitter) - Apr 28, 2022
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
The adoption of relugolix for treatment of prostate cancer (PCa) in a large community medical oncology practice. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4023;
The HERO trial showed that relugolix, a newer oral therapy, is associated with lower rates of cardiovascular events compared to leuprolide. While having at least one cardiovascular risk factor is a consideration for patients to either start with or switch to relugolix, the large majority of our patients still received first-line therapy with leuprolide.
- tamsulosin / Generic mfg., goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Profiling of clinically relevant subgroups of asymptomatic or mild-symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients using PSA and testosterone levels and deep learning. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3744;
P3
Model predictions also suggest complex interactions among many clinical features that might be important modulators of key clinical traits and outcome. Further work is required to validate this approach to anticipate the clinical course of asymptomatic or mildly symptomatic mCRPC patients and help to better decide when to start appropriate therapy.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU). (Available On Demand; 256) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3681;
P3
Although higher BMI has been associated with poorer outcomes, we did not observe a similar trend with T responses. A numerically lower PSA response was seen in obese patients.
- enzalutamide capsule / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg.
Feasibility of a novel wrist-worn thermal device for management of vasomotor symptoms in patients with prostate cancer. (Available On Demand; 250) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3675;
P=N/A
Results of this study support the feasibility of use of the thermal device for management of bothersome hot flashes in PCa survivors. Future randomized controlled studies are warranted to evaluate patient reported outcomes related to frequency and severity of VMS, sleep quality, fatigue, and overall QOL, in addition to defining the potential utility of the Embr thermal device in PCa survivors experiencing VMS.
- leuprolide acetate for depot suspension / Generic mfg., tamoxifen / Generic mfg.
Adherence to different adjuvant endocrine therapies in HR+ HER2-breast cancer and its relation to real-world progression rates. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3362;
While adherence is important for positive outcomes for all regimens, some regimens appear to be more sensitive to adherence changes with respect to RWD-ORR. Further analysis including disease risk factors is needed to explain ORR - PDC relationship.TAM- tamoxifen; AI aromatase inhibitors.*GLM with AI, Tamoxifen as reference treatment group.†p<0.05
- Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa). (Available On Demand; 296) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3222;
This may be an area amenable to intervention to improve outcomes in young women. However, larger studies are needed to elucidate the optimal E2 target on OFS and clinical implications of incomplete E2 suppression on ultrasensitive assays.
- || Sutent (sunitinib) / Pfizer
Trial primary completion date: Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) - Apr 27, 2022
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
However, larger studies are needed to elucidate the optimal E2 target on OFS and clinical implications of incomplete E2 suppression on ultrasensitive assays. Trial primary completion date: Dec 2021 --> Dec 2022
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Apr 27, 2022
P2, N=19, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Mar 2020 --> Apr 2023
- | Nubeqa (darolutamide) / Bayer, Orion Corp, Erleada (apalutamide) / J&J
Journal: Hormonal Therapy for Prostate Cancer. (Pubmed Central) - Apr 26, 2022
The purpose of this review is to provide an assessment of hormonal therapies for the various clinical states of prostate cancer. The advancement of today's standard of care will require an accounting of an individual's androgen physiology that also has recently recognized germline determinants of peripheral androgen metabolism, which include HSD3B1 inheritance.
- ||||| leuprolide acetate for depot suspension / Generic mfg., Orgovyx (relugolix) / Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Clinical: Relugolix or leuprolide for a prostate cancer patient at high risk for CVD? We discuss that—and much more—in our newest Virtual Practice here: https://t.co/RWHe2HbCE7 with @CaPsurvivorship, @PBarataMD, and Matthew Smith, MD, PhD #pcsm (Twitter) - Apr 25, 2022
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate. (Pubmed Central) - Apr 24, 2022
Notably, higher C and faster T were obtained with the MGE-containing formulation, and the BA increased with increasing MGE content in the formulation, suggesting that LA migration into the systemic circulation and its stability might be enhanced by MGE. These results may support the development of self-administered formulations of peptide drugs as well as nucleic acids, which are easily metabolized in the skin.
- |||| leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty (clinicaltrials.gov) - Apr 21, 2022
P4, N=80, Not yet recruiting, Sponsor: Takeda
- | Firmagon (degarelix) / Astellas, Ferring
Journal: Letter by Ng et al Regarding Article, "Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial". (Pubmed Central) - Apr 19, 2022
These results may support the development of self-administered formulations of peptide drugs as well as nucleic acids, which are easily metabolized in the skin. No abstract available
- | leuprolide acetate for depot suspension / Generic mfg.
Preclinical, Journal: Antibiotic Therapy and Vaginal Microbiota Transplantation Reduce Endometriosis Disease Progression in Female Mice via NF-κB Signaling Pathway. (Pubmed Central) - Apr 19, 2022
These results showed that vaginal use of antibiotics or VMT is helpful to treat endometriosis in mice. However, due to the great difference between human and mouse vaginal microbiota, its mechanism and clinical transformation application still need to be further studied in the future.
- | leuprolide acetate for depot suspension / Generic mfg.
Observational data, Journal: Knowledge, attitudes, and behaviors of practitioners supporting cancer patients in fertility preservation in DKI Jakarta: A cross-sectional study. (Pubmed Central) - Apr 19, 2022
Meanwhile, subspecialists knew most about in vitro fertilization with embryo cryopreservation and sperm cryopreservation using a GnRH agonist (such as leuprolide injection) pre-cancer treatment (13%)...The knowledge of and practices related to fertility preservation differed among general practitioners, specialists, and subspecialists. However, positive attitudes among them were similar.
- ||| leuprolide acetate for depot suspension / Generic mfg.
Oh and lastly, endometriosis as a cause of self-reported infertility/difficulty conceiving, could treatments treatment, like lupron, which decreases estrogen levels also have to do with this? Cc @MigsRunner (Twitter) - Apr 19, 2022
- | cabazitaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: ACDC-RP: Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) (clinicaltrials.gov) - Apr 15, 2022
P2, N=76, Completed, Sponsor: University Health Network, Toronto
However, positive attitudes among them were similar. Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Jul 2021 | Trial primary completion date: Dec 2021 --> May 2021
- || leuprolide acetate for depot suspension / Generic mfg.
Clinical, Journal, HEOR: Neoadjuvant Leuprolide Therapy with Radical Prostatectomy: Long-term Effects on Health-related Quality of Life. (Pubmed Central) - Apr 14, 2022
Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Jul 2021 | Trial primary completion date: Dec 2021 --> May 2021 Patients who received NADT prior to RALP do not have worse sexual function, but have worse hormonal scores for up to 2yr after surgery.
- ||| Kisqali (ribociclib) / Novartis
P3 data, Clinical Trial,Phase III, Journal: Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial. (Pubmed Central) - Apr 13, 2022
P3
The clinical benefit and overall response rates in males were consistent with the overall population. This analysis demonstrates the safety and efficacy of ribociclib in a close-to-real-world setting, supporting the use of RIB + LET in male patients with HR+, HER2- ABC.
- || leuprolide acetate for depot suspension / Generic mfg., estradiol/norethindrone oral / Generic mfg.
Clinical, Journal: Apoplectic leiomyomas: does ethnicity make a difference? a clinicopathologic study. (Pubmed Central) - Apr 12, 2022
Apoplectic leiomyomas were observed in 22.1% (77/349) of women ≤ 45 years of age compared to 11.3% (59/520) of women > 45 years of age (p < 0.0001), and this difference remained statistically significant regardless of hormone use.This is the largest study to date examining apoplectic leiomyomas in women on known hormonal therapy compared to women with uterine leiomyomas, but not on hormonal therapy. Information about hormonal therapy, ethnicity, and age can be helpful in the diagnostic interpretation of apoplectic leiomyoma.
- | Firmagon (degarelix) / Astellas, Ferring
Journal: Switching Patients With Prostate Cancer from GnRH Antagonist to Long-acting LHRH Agonist for Androgen Deprivation: Reducing Hospital Visits During the Coronavirus Pandemic. (Pubmed Central) - Apr 12, 2022
No changes in the rates of flare-ups of conditions or adverse events were observed. Switching from GnRH antagonist to a long-acting LH-RH agonist appears to be a reasonable option that does not diminish efficacy or exacerbate adverse events.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov) - Apr 11, 2022
P=N/A, N=60, Active, not recruiting, Sponsor: Medical College of Wisconsin
Switching from GnRH antagonist to a long-acting LH-RH agonist appears to be a reasonable option that does not diminish efficacy or exacerbate adverse events. Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024
- | leuprolide acetate for depot suspension / Generic mfg.
Biomarker, Enrollment closed, Trial completion date, Trial primary completion date: Menopausal Sleep Fragmentation and Body Fat Gain (clinicaltrials.gov) - Apr 11, 2022
P4, N=58, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024 Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jul 2022
- | Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P4 trial: REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov) - Apr 10, 2022
P4, N=90, Not yet recruiting, Sponsor: Emory University
- Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: Analysis of real-life data from Eudra-Vigilance database (Room 225) - Apr 10, 2022 - Abstract #AUA2022AUA_2713;
Real-life data suggest GnRH agonists are associated with higher cardiovascular AEs when compared to GnRH antagonists. Clinicians should consider these data when prescribing HT especially in young patients.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies (Room 252) - Apr 10, 2022 - Abstract #AUA2022AUA_2397;
MACE incidence in this pooled analysis was 2.8% in the relugolix group and 6.3% in the leuprolide group. Conclusions : In the pooled safety analyses of 2 randomized clinical studies in advanced prostate cancer, relugolix was generally well tolerated, with a lesser incidence of MACE relative to leuprolide.
- Nubeqa (darolutamide) / Bayer, Orion Corp, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Comparative out-of-pocket costs of treatment options in privately insured patients with advanced prostate cancer (Room 222) - Apr 10, 2022 - Abstract #AUA2022AUA_2028;
Conclusions : Patients receiving novel hormonal agents had substantially higher OOPC than other therapies. In addition to raising awareness among prescribers, these data support the inclusion of financial toxicity discussions as a part of patient counseling for these agents.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis from the Randomized Phase 3 HERO Study (Room 222) - Apr 10, 2022 - Abstract #AUA2022AUA_2025;
Conclusions : Relugolix, an oral nonpeptide GnRH receptor antagonist, was generally well tolerated in the phase 3 HERO study. Results for AE onset and duration suggest AEs occur early during treatment with varying duration depending on the type of event.
- || leuprolide acetate for depot suspension / Generic mfg.
Clinical, Review, Journal: A case report of precocious puberty related to Rett syndrome and a literature review. (Pubmed Central) - Apr 9, 2022
PP was controlled after treatment with leuprorelin 3.75 mg for one year. In addition, the genetic and phenotypic spectrum of previously reported cases of Rett syndrome with precocious puberty are reviewed and summarized.
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Lipid-Based Ionic-Liquid-Mediated Nanodispersions as Biocompatible Carriers for the Enhanced Transdermal Delivery of a Peptide Drug. (Pubmed Central) - Apr 9, 2022
In this study, we report the formulation of a peptide-LBIL complex microencapsulated in an oil phase as a potential carrier for the transdermal delivery of leuprolide acetate as a model hydrophilic peptide...In vitro and in vivo cytotoxicity studies of the IL/O-NDs revealed the biocompatibility of the LBIL-based formulations. These results indicated that IL/O-NDs are promising biocompatible carriers for lipid-peptide TDDSs.